Cargando…

Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Katharine, Goldschmidt, Robert, Turk, Mary, Wesseling, Jelle, Stork-Sloots, Lisette, de Snoo, Femke, Cristofanilli, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621695/ https://www.ncbi.nlm.nih.gov/pubmed/26424167 http://dx.doi.org/10.1007/s10549-015-3587-9

Ejemplares similares

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance
por: Viale, Giuseppe, et al.
Publicado: (2016)

Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
por: Finn, Richard S., et al.
Publicado: (2020)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
por: Whitworth, Pat, et al.
Publicado: (2014)

Prognostic impact of breast cancer subtypes in elderly patients
por: Bergen, E. S., et al.
Publicado: (2016)

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression
por: Bryant, Richard J., et al.
Publicado: (2020)

Revisiting the JOQUER trial: stratification of primary Sjögren’s syndrome and the clinical and interferon response to hydroxychloroquine
por: Collins, Alexis, et al.
Publicado: (2021)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Defining the noninferiority margin and analysing noninferiority: An overview
por: Althunian, Turki A., et al.
Publicado: (2017)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
por: Baron, Paul, et al.
Publicado: (2015)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention
por: Flowers, Chris I., et al.
Publicado: (2013)

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6
por: Strain, W. David, et al.
Publicado: (2022)

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial
por: DeCensi, Andrea, et al.
Publicado: (2014)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
por: Inoue, Kenichi, et al.
Publicado: (2016)

Patient-Specific Data Fusion Defines Prognostic Cancer Subtypes
por: Yuan, Yinyin, et al.
Publicado: (2011)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema
por: He, Chaobin, et al.
Publicado: (2018)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Isoform-level gene signature improves prognostic stratification and accurately classifies glioblastoma subtypes
por: Pal, Sharmistha, et al.
Publicado: (2014)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

The Effectiveness of Group Logo Therapy on the Hope among the Leukemic Patients
por: Ebrahimi, Nazila, et al.
Publicado: (2014)

On the relevance of prognostic information for clinical trials: A theoretical quantification
por: Siegfried, Sandra, et al.
Publicado: (2022)

A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone
por: Lin, Jianqing, et al.
Publicado: (2016)

Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
por: Silverman, Stuart L.
Publicado: (2010)

Transcription levels and prognostic significance of the NFI family members in human cancers
por: Li, Yuexian, et al.
Publicado: (2020)

Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer
por: Davidson, Michael, et al.
Publicado: (2017)

Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome
por: Lövdahl, Jenny, et al.
Publicado: (2022)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Multi-disciplinary community-based group intervention for fibromyalgia: a pilot randomized controlled trial
por: Turcotte, Kara, et al.
Publicado: (2023)

Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI
por: Zhao, Xiaoxiao, et al.
Publicado: (2021)

The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials
por: Bloom, Diane, et al.
Publicado: (2017)

Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer
por: Haynes, Ben P., et al.
Publicado: (2021)

Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
por: van Roozendaal, L. M., et al.
Publicado: (2016)

Barriers and facilitators for leading nursing homes through the COVID‐19 pandemic: A focus group study in Norway
por: Samdal, Gro Beate, et al.
Publicado: (2023)

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis
por: Mease, Philip J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qg6j9kece6609232mse28bnen7